Abstract
The European chronic thromboembolic pulmonary hypertension (CTEPH) registry (Pepke-Zaba et al, Circulation 2011) analyzed the effect of pulmonary endarterectomy (PEA) on long-term outcome of CTEPH patients (Delcroix et al, Circulation 2016). Since then, 2 other treatments have been introduced: balloon pulmonary angioplasty (BPA), and the guanylate cyclase stimulator riociguat. Our new registry aimed to evaluate current therapeutic approaches in a worldwide context.
1009 newly diagnosed, consecutive patients were included between Feb 2015 and Sept 2016, and followed until Sep 2019. Overall, 605 patients (60%) underwent PEA and 185 (18%) BPA; 76 % of the 219 ‘no PEA/BPA’ patients were treated with PH drugs, and 38% and 78% of the PEA and BPA patients, respectively. Median age at diagnosis was higher in the BPA and 'no PEA/BPA' groups: 66 and 69 vs 60 years (p<0.001), while pulmonary vascular resistance was similar, averaging 638 dyn.s.cm-5 .
During an observation period of >3 (up to 5.6) years, death was reported in 7, 10 and 27% of the patients treated by PEA, BPA and 'no PEA/BPA', respectively (p<0.001). KM survival curves (Figure 1), showed more than 90% 3-year survival in the patients undergoing interventional treatments. In the ‘no PEA/BPA' group, 3-year survival was 70%, reaching 85% for patients receiving riociguat (n=92).
This new registry reveals important differences in patient outcome according to therapeutic approaches.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA174.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021